Hrt Financial LP Prothena Corp Public LTD CO Transaction History

Hrt Financial LP

  • $18.1 Billion
  • Q3 2024

A detailed history of Hrt Financial LP transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Hrt Financial LP holds 41,809 shares of PRTA stock, worth $643,858. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,809
Previous 23,422 78.5%
Holding current value
$643,858
Previous $483,000 44.72%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$16.73 - $24.79 $307,614 - $455,813
18,387 Added 78.5%
41,809 $699,000
Q2 2024

Aug 12, 2024
BUY
$19.54 - $26.15 $457,665 - $612,485
23,422 New
23,422 $483,000
Q4 2023

Feb 09, 2024
SELL
$32.31 - $52.32 $179,482 - $290,637
-5,555 Reduced 48.48%
5,904 $214,000
Q3 2023

Nov 13, 2023
BUY
$47.3 - $70.6 $542,010 - $809,005
11,459 New
11,459 $552,000
Q1 2023

May 12, 2023
BUY
$46.97 - $58.27 $304,600 - $377,880
6,485 New
6,485 $314,000
Q3 2022

Nov 14, 2022
BUY
$25.16 - $60.63 $311,053 - $749,568
12,363 New
12,363 $749,000
Q1 2021

May 17, 2021
SELL
$11.0 - $28.24 $185,295 - $475,702
-16,845 Closed
0 $0
Q4 2020

Feb 16, 2021
SELL
$10.12 - $13.94 $172,363 - $237,426
-17,032 Reduced 50.28%
16,845 $202,000
Q3 2020

Nov 13, 2020
BUY
$9.93 - $13.47 $336,398 - $456,323
33,877 New
33,877 $338,000
Q1 2020

May 15, 2020
SELL
$7.54 - $15.77 $103,539 - $216,553
-13,732 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$7.48 - $17.01 $27,810 - $63,243
3,718 Added 37.13%
13,732 $217,000
Q3 2019

Nov 14, 2019
BUY
$6.89 - $10.45 $68,996 - $104,646
10,014 New
10,014 $78,000

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $723M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email